Navigation Links
Virginia G. Piper Cancer Center vaccine study hopes to improve pancreatic cancer treatment
Date:6/13/2014

SCOTTSDALE, Ariz. June 12, 2014 Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer.

The Phase 2B clinical trial of CRS-207 and GVAX Pancreas vaccines is open at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen), where cancer patients are treated with promising new drugs.

Participants in the study, named ECLIPSE (Efficacy of Combination Listeria/GVAX Immunotherapy in the Pancreatic Cancer Setting), will be randomized so patients receive only the CRS-207 vaccine, or that vaccine combined with the GVAX Pancreas vaccine and low doses of cyclophosphamide. A third group of patients will receive a standard chemotherapy.

"This is a very innovative approach using immunotherapy to treat pancreatic cancer," explained Dr. Erkut Borazanci, M.D., M.S., medical oncologist and Drug Development Scholar at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and the study's lead investigator.

The CRS-207 vaccine is a weakened form of the bacteria, Listeria monocytogenes, that has been genetically modified to be safe for human use, while retaining its ability to stimulate the immune system. Specifically, CRS-207 has been engineered to stimulate an immune response against the tumor-associated antigen mesothelin, which is present at high levels on pancreatic cancer cells.

The GVAX vaccine is composed of genetically modified, inactivated pancreatic cancer cells that have been shown to stimulate the immune system's anticancer activity. The vaccine is given with a low-dose of a common cancer drug called cyclophosphamide to boost the effectiveness of the vaccine.

In a recently completed Phase 2A trial in 93 patients with advanced pancreatic cancer, survival was improved in patients who received the combination regimen of CRS-207, GVAX and cyclophosphamide (6.1 months), compared to 3.9 months for those who received only cyclophosphamide and GVAX. The immunotherapies were well-tolerated, with no serious treatment-related adverse side effects.

Virginia G. Piper Cancer Center Clinical Trials is among the first 11 centers in the United States participating in the study. The drug was developed by Aduro BioTech, Inc., a clinical-stage immunotherapy company located in Berkeley, Calif. A total of 240 patients are expected to be treated at more than 20 clinical trial sites in North America.

"If this study is successful, we hope that this form of immunotherapy will become widely available across the country to treat patients with advanced pancreatic cancer," added Dr. Borazanci.

Pancreatic cancer is difficult to treat and is the fourth leading cause of cancer-related death in the U.S. Tumors may grow in the pancreas without any early symptoms, which means that the disease is often in an advanced stage when it is diagnosed, and survival remains poor.

Virginia G. Piper Cancer Center Clinical Trials is known worldwide for its expertise in studying new treatments for pancreatic cancer.

Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713 or via email at clinicaltrials@shc.org. Additional information is available at http://www.clinicaltrials.gov (NCT02004262).


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Virginia Tech updates football helmet ratings, 5 new helmets meet 5-star mark
2. Virginia Tech scientists out for blood when it comes to stopping malaria
3. Class Action Lawsuit Filed on Behalf of West Virginia Residents Affected by Recent Chemical Spill
4. West Virginia Business Owners Represented in Class Action Lawsuit over Elk River Chemical Spill
5. The Bell Law Firm Filing Class Action Complaints on Behalf of West Virginia Contaminated Water Victims
6. Virginia Tech researchers find novice teen drivers easily fall into distraction, accidents
7. The Science Museum of Virginia Receives Largest Private Gift in Its History
8. Audiologists at Virginia Hearing Consultants in Norfolk VA Share Warnings about Everyday Ototoxic Drugs
9. Audiologists at Maico Audiological Services in Newport News Virginia Advise Consumers about Drugs that Lead to Hearing Loss
10. Northern Virginia Real Estate Company Pasquali Realty Group Suggests These New Year’s Resolutions For Homeowners
11. Northern Virginia Real Estate Company Pasquali Realty Group Announces Prices Up in November
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... throughout Arkansas that offers insurance and financial preparation services, is providing an update ... City Rescue organization. , Rock City Rescue is a locally recognized nonprofit that ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of sub-acute ... of a disaster drill on October 3rd. , Apple Rehab participated with the Shelton ... well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The LTC-MAP ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: